News just out is very encouraging! "As previou
Post# of 504
"As previously disclosed, UHP submitted to the FDA an Investigational Device Exemption application (IDE) last November, the approval of which is a precondition to enroll patients in the planned study. The company held discussions with the FDA prior to year end and again on January 28th regarding the FDA's comments on its application, which resolved certain concerns regarding preclinical testing protocols. With these matters resolved, the company expects to submit to the FDA its additional responses addressing all preclinical and clinical comments, in early February."
"To fund the clinical study and other activities UHP has successfully raised over $400,000 through private placement transactions with longtime existing shareholders and is in discussions to secure additional funds under a similar strategy. To boost investor interest and demand for its securities, the company has applied to OTC Markets for an uplisting of its shares to trade on the OTCQB exchange from the current OTCPK platform. OTC Markets is reviewing the application materials and there can be no assurance that this application will be approved. The company does not currently anticipate drawing upon its existing stock purchase agreement with White Lion Capital."